# A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects

> **NCT00722358** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 15 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** BMS-650032
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00722358
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2011-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00722358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00722358, "A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00722358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*